Simon Piggott

Learn More
BACKGROUND Indacaterol is a novel, once-daily (o.d.) inhaled, long-acting beta2-agonist in development for chronic obstructive pulmonary disease (COPD). This 12-week, double-blind study compared the efficacy, safety, and tolerability of indacaterol to that of placebo in patients with moderate-to-severe COPD. METHODS Efficacy variables included 24-h trough(More)
BACKGROUND Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β2-agonist for the treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind study compared the bronchodilator efficacy of indacaterol with that of placebo and tiotropium in patients with moderate-to-severe COPD. METHODS In an incomplete-block,(More)
The basal metabolic rate (BMR) and diet-induced thermogenesis (DIT) in 11 Asians (4 men, 7 women) who had lived in Britain for longer than 2 years were compared with a matched group of Europeans. The mean basal oxygen consumption was 226 ml O2/min in the Asians and 218 ml O2/min in the Europeans, values not significantly different. When BMR was expressed in(More)
BACKGROUND Tobramycin powder for inhalation (TIP) is a drug-device combination designed to reduce treatment time and improve ease of use compared with tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients. However, the ability of patients to use dry powder inhalers, and the efficacy of the treatments, may vary by age. METHODS The(More)
BACKGROUND Tobramycin inhalation powder (TIP) was reported to be effective in two Phase III studies in patients with cystic fibrosis (CF) chronically infected with Pseudomonas aeruginosa (Pa). The EDIT study evaluated the efficacy and safety of TIP manufactured by an improved process in CF subjects aged 6-21 years. METHODS CF patients with a forced(More)